Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25283470 | 1.00 | CTSL (0.52) | CTSLKMT2AMAPK1ITGB3ITGA2B | |
| SCHEMBL25285287 | 0.92 | CTSL (0.53) | CTSLKMT2AITGB3ITGA2BSYK | |
| SCHEMBL25285288 | 0.92 | CTSL (0.53) | CTSLKMT2AITGB3ITGA2BSYK | |
| SCHEMBL24640641 | 0.83 | HRH3 (0.43) | CTSLKMT2AMAPK1MEN1ALDH1A1 | |
| SCHEMBL5634305 | 0.81 | CTSL (0.51) | CTSLKMT2AMAPK1ITGB3ITGA2B | |
| SCHEMBL25238574 | 0.80 | SMN1; SMN2 (0.48) | KMT2AFKBP1AALDH1A1 | |
| SCHEMBL25288524 | 0.80 | SMN1; SMN2 (0.48) | KMT2AFKBP1AALDH1A1 | |
| SCHEMBL4510998 | 0.80 | CTSL (0.48) | CTSLKMT2ASYKMEN1MAPT | |
| SCHEMBL4511000 | 0.80 | CTSL (0.48) | CTSLKMT2ASYKMEN1MAPT | |
| SCHEMBL30313012 | 0.79 | DRD2 (0.57) | CTSLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346579-A1 | PYRIDAZINONE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-11-13 | — | — | US | disclosed |
| WO-2023116824-A1 | PYRIDAZINONE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346579-A1 | PYRIDAZINONE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | CYP4F11, WEE1, CYP4A11 | CTSL 949/4885KMT2A 3637/4885MAPK1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.